Last reviewed · How we verify

Once-daily insulin detemir

Sydney Children's Hospitals Network · Phase 3 active Small molecule

Once-daily insulin detemir is a Long-acting basal insulin analog Small molecule drug developed by Sydney Children's Hospitals Network. It is currently in Phase 3 development for Type 1 diabetes mellitus in pediatric patients, Type 2 diabetes mellitus in pediatric patients. Also known as: Levemir.

Insulin detemir is a long-acting basal insulin that binds to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in peripheral tissues while suppressing hepatic glucose production.

Insulin detemir is a long-acting basal insulin that binds to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in peripheral tissues while suppressing hepatic glucose production. Used for Type 1 diabetes mellitus in pediatric patients, Type 2 diabetes mellitus in pediatric patients.

At a glance

Generic nameOnce-daily insulin detemir
Also known asLevemir
SponsorSydney Children's Hospitals Network
Drug classLong-acting basal insulin analog
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

Insulin detemir is a modified human insulin analog with a fatty acid chain attached, which allows it to bind reversibly to albumin in the bloodstream, creating a depot effect that extends its duration of action to approximately 24 hours. This provides steady basal insulin coverage with a relatively flat pharmacokinetic profile, reducing the risk of hypoglycemic episodes compared to shorter-acting insulins. It is administered once daily and is used to maintain baseline insulin levels in patients with type 1 and type 2 diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Once-daily insulin detemir

What is Once-daily insulin detemir?

Once-daily insulin detemir is a Long-acting basal insulin analog drug developed by Sydney Children's Hospitals Network, indicated for Type 1 diabetes mellitus in pediatric patients, Type 2 diabetes mellitus in pediatric patients.

How does Once-daily insulin detemir work?

Insulin detemir is a long-acting basal insulin that binds to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in peripheral tissues while suppressing hepatic glucose production.

What is Once-daily insulin detemir used for?

Once-daily insulin detemir is indicated for Type 1 diabetes mellitus in pediatric patients, Type 2 diabetes mellitus in pediatric patients.

Who makes Once-daily insulin detemir?

Once-daily insulin detemir is developed by Sydney Children's Hospitals Network (see full Sydney Children's Hospitals Network pipeline at /company/sydney-children-s-hospitals-network).

Is Once-daily insulin detemir also known as anything else?

Once-daily insulin detemir is also known as Levemir.

What drug class is Once-daily insulin detemir in?

Once-daily insulin detemir belongs to the Long-acting basal insulin analog class. See all Long-acting basal insulin analog drugs at /class/long-acting-basal-insulin-analog.

What development phase is Once-daily insulin detemir in?

Once-daily insulin detemir is in Phase 3.

What are the side effects of Once-daily insulin detemir?

Common side effects of Once-daily insulin detemir include Hypoglycemia, Injection site reactions, Weight gain, Lipodystrophy.

What does Once-daily insulin detemir target?

Once-daily insulin detemir targets Insulin receptor and is a Long-acting basal insulin analog.

Related